~~<i id='4E461B0E29'><strike id='4E461B0E29'><tt id='4E461B0E29'><pre id='4E461B0E29'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

explore

author：focus 2025-09-30 19:03:23 - browse：92

Blue nerve cell surrounded by red antibodies. -- health coverage from STAT — Adobe

Belgian drugmaker Argenx said Monday that its antibody treatment called Vyvgart significantly delayed the progression of an autoimmune nerve disorder that causes people to lose feeling and muscle strength in the arms and legs.

The positive outcome — a 61% reduction in the risk of relapse compared to a placebo — achieved the main goal of a Phase 3 clinical trial designed to demonstrate Vyvgart’s benefit for patients with chronic inflammatory demyelinating polyneuropathy, or CIDP.

“We hit the bullseye,” said Argenx CEO Tim Van Hauwermeiren.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： NIH trials fail to test meaningful long Covid therapies, experts say

Wikipedia

hotspot

entertainment

explore

hotspot

MelEvans/APMerckannouncedMondayitwillacquireHarpoonTherapeuticsanditspipelineofimmune-basedcancerdru

WSS

Shkreli is convicted of fraud. Can pharma finally slam the door on him?

In shift, Texas to cover initial consult for Afghan baby's gene therapy

Police still searching for prisoner who escaped from NYC hospital

What to know about Virgin Galactic's 1st mission taking paying customers to space

Wegovy trial has doctors encouraged over new possibilities

Allen Institute goes after foundational questions, CEO Costa says

hotspot

explore

Wikipedia

Hepatitis C has a cure — but many Americans still lack access to it

Male doctors called my cancer incurable. A female doctor showed it wasn't

Medicare details structure of new drug price negotiation program

Allen Institute goes after foundational questions, CEO Costa says

Sports medicine is finally prioritizing gender equality

Boston Scientific acquires urology company Axonics for $3.7 billion

United colonoscopy coverage change 'may cost lives,' doctors say

Arena BioWorks launches in Cambridge to speed drug discovery

Medicare details structure of new drug price negotiation program

Wayne Brady comes out as pansexual: 'Free to love whomever I want'

hotspot

Listen: Merck v. USA, the best of ASCO, and Leqembi at the FDA

NIH trials fail to test meaningful long Covid therapies, experts say

Jack Smith previously got search warrant for Trump's Twitter, new court docs show

Medicare Advantage coverage denials need scrutiny, senators say

Gene therapy denied for Afghan refugee whose father aided U.S.

Emergent cuts jobs, executive role in business shake

entertainment

explore

hotspot

hotspot